Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesOther Gross PP&E AdjustmentsShares Issued
Ratios

Theravance Biopharma (TBPH) Non-Current Receivables (2017 - 2020)

Historic Non-Current Receivables for Theravance Biopharma (TBPH) over the last 4 years, with Q2 2020 value amounting to $4.0 million.

  • Theravance Biopharma's Non-Current Receivables rose 787.55% to $4.0 million in Q2 2020 from the same period last year, while for Jun 2020 it was $4.0 million, marking a year-over-year increase of 787.55%. This contributed to the annual value of $3.7 million for FY2019, which is N/A changed from last year.
  • Latest data reveals that Theravance Biopharma reported Non-Current Receivables of $4.0 million as of Q2 2020, which was up 787.55% from $4.0 million recorded in Q1 2020.
  • In the past 5 years, Theravance Biopharma's Non-Current Receivables registered a high of $8.2 million during Q4 2017, and its lowest value of $3.1 million during Q3 2018.
  • Moreover, its 4-year median value for Non-Current Receivables was $3.7 million (2019), whereas its average is $4.5 million.
  • As far as peak fluctuations go, Theravance Biopharma's Non-Current Receivables crashed by 6120.2% in 2018, and later skyrocketed by 1756.28% in 2019.
  • Theravance Biopharma's Non-Current Receivables (Quarter) stood at $8.2 million in 2017, then plummeted by 61.78% to $3.1 million in 2018, then grew by 17.6% to $3.7 million in 2019, then increased by 8.26% to $4.0 million in 2020.
  • Its Non-Current Receivables was $4.0 million in Q2 2020, compared to $4.0 million in Q1 2020 and $3.7 million in Q4 2019.